IMV News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.09.23	IMV Accepts an Offer from its Secured Lenders for the Sale of its Intellectual Property Assets (Businesswire)
08.05.23	IMV Receives NASDAQ Delisting Notice (Businesswire)
01.05.23	IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives (Businesswire)
31.03.23	IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (Businesswire)
27.03.23	IMV Inc. Announces Changes to Its Board of Directors (Businesswire)
16.03.23	IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results (Businesswire)
09.03.23	IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023 (Businesswire)
13.02.23	IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial (Businesswire)
08.01.23	IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S (Businesswire)
20.12.22	IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (Businesswire)
16.12.22	IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (Businesswire)
15.12.22	IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL (Businesswire)
13.12.22	IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split (Businesswire)
07.12.22	IMV Shareholders Approve Reverse Stock Split at 88% (Businesswire)
25.11.22	IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities (Businesswire)
10.11.22	IMV Inc. Announces Third Quarter 2022 Financial and Operational Results (Businesswire)
08.11.22	IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022 (Businesswire)
30.09.22	IMV Provides an Update on The VITALIZE Trial (Businesswire)
15.09.22	IMV To Slash Workforce By Around One Third (RTTNews)
15.09.22	IMV Inc. Announces Strategic Reorganization (Businesswire)
01.09.22	IMV Inc. to Present at Two Investor Conferences in September (Businesswire)
11.08.22	IMV Inc. Announces Second Quarter 2022 Financial and Operational Results (Businesswire)
05.08.22	IMV Re-Establishes Its At-the-Market Facility Under Renewed Base Shelf Prospectus (Businesswire)
04.08.22	IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022 (Businesswire)
08.07.22	IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (Businesswire)
30.06.22	IMV Announces Annual and Special Meeting of Shareholders Voting Results (Businesswire)
22.06.22	IMV Strengthens Its Financial Position With the $US10 Million Drawdown From Its Existing Long-Term Debt Facility (Businesswire)
17.05.22	IMV Inc. to Present at the H.C. Wainwright Global Investment Conference (Businesswire)
13.05.22	IMV Inc. Announces First Quarter 2022 Financial and Operational Results (Businesswire)
06.05.22	IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022 (Businesswire)
28.04.22	IMV’s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting (Businesswire)
22.04.22	IMV Inc. Names Michael P. Bailey Chairman of The Board (Businesswire)
08.04.22	IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting (Businesswire)
06.04.22	IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting (Businesswire)
04.04.22	IMV Inc. to Present at Two Upcoming Investor Conferences (Businesswire)
17.03.22	IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results (Businesswire)
10.03.22	IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022 (Businesswire)
09.03.22	IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022 (Businesswire)
17.02.22	IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform (Businesswire)
12.01.22	IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL (Businesswire)
05.01.22	IMV Inc. to Present at Two Upcoming Investor Events (Businesswire)
22.12.21	IMV Names Andrew Hall CEO - Quick Facts (RTTNews)
22.12.21	IMV Appoints Andrew Hall as Chief Executive Officer (Businesswire)
21.12.21	IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts (Businesswire)
20.12.21	IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility (Businesswire)
02.12.21	Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress (Businesswire)
30.11.21	IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer (Businesswire)
22.11.21	IMV Says CFO Pierre Labb Will Retire In End March - Quick Facts (RTTNews)
09.06.21	IMV Announces Appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer And Addition of Clinical Advisor (Businesswire)
13.05.21	IMV Inc. to Present at Two Upcoming Investor Conferences (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu IMV Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten